A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Healthy

Interventions

DRUG

PF-04895162

Tablets, 300 mg, single, 1 day

DRUG

PF-04895162

Tablets, 300 mg, twice a day, 14 days

DRUG

PF-04895162

Tablets, to be decided, twice a day, 14 days

DRUG

Placebo

Tablets, twice a day, 14 days

Trial Locations (1)

Pfizer Investigational Site, New Haven